Navigation Links
Eurand Added to NASDAQ Biotechnology Index
Date:11/12/2007

AMSTERDAM, Netherlands, Nov. 12 /PRNewswire-FirstCall/ -- Eurand N.V. (Nasdaq: EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, announced today that the Company has been selected for inclusion in the NASDAQ Biotechnology Index (Nasdaq: NBI), effective November 19, 2007.

Gearoid Faherty, Chief Executive Officer of Eurand, commented, "We are delighted to be included in this important NASDAQ index and believe it is further validation of our position in the life sciences industry."

The NASDAQ Biotechnology Index includes securities of NASDAQ-listed companies that meet eligibility criteria including market capitalization minimums, trading volume minimums, and ICB classification. The index is ranked on a semi-annual basis in May and November. More information about the NBI is available at http://www.nasdaq.com

About Eurand

Eurand is a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. Eurand has had four products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Eurand has completed two phase III clinical trials on its lead product candidate, Zentase, for the treatment of Exocrine Pancreatic Insufficiency and filed a rolling NDA for this product which the company anticipates to complete by the end of 2007. Eurand's technology platforms include bioavailability enhancement of poorly soluble drugs, customized release, taste-making/fast-dissolving formulations and drug conjugation.

Eurand is a global company with facilities in the USA and Europe. For more information, visit Eurand's website at http://www.eurand.com.

This release, and oral statements made with respect to information contained in this release, constitutes forward-looking statements. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact including, but not limited to our plans for our NDA filing, enrollment and future plans for our clinical trials, progress of and reports of results from clinical studies, clinical development plans and product development activities. The words "potentially", "could", "calls for" and similar expressions also identify forward-looking statements. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Factors that could affect actual results include risks associated with the possibility that the FDA refuses to approve our NDA; the outcome of any discussions with the FDA; and unexpected delays in preparation of materials for submission to the FDA as a part of our NDA filing. Forward- looking statements contained in this press release are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Actual events could differ materially from those anticipated in the forward- looking statements.

Contacts:

Mario Crovetto Nick Laudico/Elizabeth Scott

Chief Financial Officer The Ruth Group

Eurand N.V. 646-536-7030/7014

+39 02 95428 521 nlaudico@theruthgroup.com

mario.crovetto@eurand.com escott@theruthgroup.com


'/>"/>
SOURCE Eurand N.V.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
4. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
5. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
6. Kendle to Ring Opening Bell at NASDAQ Stock Market on August 22
7. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
8. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Lajollacooks4u is proud to announce it has become the premiere team-building ... challenges for companies around the world, such as Illumina, HP and Qualcomm, and is ranked ... its increasing popularity is due to its new team building format, a way for teams ...
(Date:3/23/2017)... 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) (NW ... therapies for solid tumor cancers, today announced that ... it announced last Friday, March 17, 2017. ... investors securities totaling 28,843,692 shares, comprised of 18,843,692 ... shares of Class C Warrants pre-funded at the ...
(Date:3/23/2017)... March 23, 2017  GlobeImmune, Inc. today announced it ... sale of 12,835,490 shares of its common stock to ... companies. In connection with the sale of its common stock, ... and issue to GlobeImmune 200,000 shares, an estimated $2.0 ... "We are pleased to enter into this strategic ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... recently selected by the Connecticut Technology Council (CTC) as a 2017 Women of ... thirteenth annual Women of Innovation Awards Dinner. , The dinner recognizes women accomplished ...
Breaking Biology Technology:
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber ... announced it has led a $3.5 million investment in  ... platform. Strategic Cyber Ventures is DC based and is ... Hank Thomas . Ron Gula , also ... Ventures, also participated in this series A round of ...
(Date:2/21/2017)... Ore. , Feb. 22, 2017  IBM (NYSE: ... (Avamere Health Services, Infinity Rehab, Signature Hospice, Home Health, ... will apply the power of IBM cognitive computing to ... centers. By analyzing data streaming from sensors in senior ... and environmental conditions, and obtain deeper learnings into the ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
Breaking Biology News(10 mins):